ANAB vs BDX · rev $234.6M vs P/E 34, rev $21.84B
AnaptysBio Inc (ANAB) versus Becton Dickinson and Company (BDX) — a side-by-side from cached financials, not a winner call.
AnaptysBio Inc (ANAB) is a biotechnology company listed on NASDAQ.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Latest reported ANAB revenue for 2025-12-31 was $234.6M. Net income was -$13.2M. Revenue was up 157.0% from 2024-12-31 to 2025-12-31. ANAB currently screens at market cap $1.62B.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
ANAB currently screens at market cap $1.62B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Not investment advice. Open the ANAB and BDX stock pages for the full models.
Not investment advice.